{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:20:35Z","timestamp":1773868835950,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["1U54HD071594"],"award-info":[{"award-number":["1U54HD071594"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins & Other Lipid Mediators"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.prostaglandins.2017.09.005","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T18:17:33Z","timestamp":1505758653000},"page":"93-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Human retinal endothelial cells and astrocytes cultured on 3-D scaffolds for ocular drug discovery and development"],"prefix":"10.1016","volume":"134","author":[{"given":"Kay D.","family":"Beharry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria B.","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Lazzaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwin M.","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Salomone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob V.","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0005","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1542\/peds.2004-1180","article-title":"Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs","volume":"115","author":"Gilbert","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0010","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jaapos.2012.09.004","article-title":"An update on progress and the changing epidemiology of causes of childhood blindness worldwide","volume":"16","author":"Kong","year":"2012","journal-title":"J. AAPOS"},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/sj.jp.7211040","article-title":"Arterial oxygen fluctuation and retinopathy of prematurity in very-low-birth-weight infants","volume":"24","author":"York","year":"2004","journal-title":"J. Perinatol."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jpeds.2010.01.046","article-title":"A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity","volume":"157","author":"Di Fiore","year":"2010","journal-title":"J. Pediatr."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0025","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/pr.2012.132","article-title":"The relationship between patterns of intermittent hypoxia and retinopathy of prematurity in preterm infants","volume":"72","author":"Di Fiore","year":"2012","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0030","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1542\/peds.111.2.339","article-title":"Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants?","volume":"111","author":"Chow","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.semperi.2015.12.006","article-title":"Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity","volume":"40","author":"Beharry","year":"2016","journal-title":"Semin. Perinatol."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12887-016-0551-8","article-title":"Off-label use and harmful potential of drugs in a NICU in Brazil: a descriptive study","volume":"16","author":"de Souza","year":"2016","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0045","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/cpt.166","article-title":"Neonatal drug therapy: the first frontier of therapeutics for children","volume":"98","author":"Allegaert","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0055","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/eye.2008.21","article-title":"Adult vitreous structure and postnatal changes","volume":"22","author":"Le Goff","year":"2008","journal-title":"Eye"},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0060","series-title":"Ageing and Human Visual Function","first-page":"45","article-title":"Ageing changes in the vitreous","author":"Balazs","year":"1982"},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0065","first-page":"3500","article-title":"Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocyte template and specific R-cadherin adhesion","volume":"43","author":"Dorrell","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0070","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1167\/iovs.03-1169","article-title":"Astrocyte-endothelial cell relationships during human retinal development","volume":"45","author":"Chan-Ling","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0075","first-page":"2148","article-title":"Degeneration of astrocytes in feline retinopathy of prematurity causes failure of the blood-retinal barrier","volume":"33","author":"Chan-Ling","year":"1992","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0080","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/glia.20997","article-title":"Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina","volume":"58","author":"Weidemann","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0085","first-page":"415","article-title":"Treatment of retinopathy of prematurity with topical ketorolac tromethamine: a preliminary study","volume":"7","author":"Avila-Vazquez","year":"2004","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3928\/01913913-20100920-01","article-title":"Effectiveness of ketorolac tromethamine in prevention of severe retinopathy of prematurity","volume":"48","author":"Giannantonio","year":"2011","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0095","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/pr.2016.105","article-title":"Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathy","volume":"80","author":"Aranda","year":"2016","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0100","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/adc.54.12.946","article-title":"Maturation of caffeine elimination in infancy","volume":"54","author":"Aranda","year":"1979","journal-title":"Arch. Dis. Child"},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0009-9236(01)13478-8","article-title":"Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus","volume":"70","author":"Van Overmeire","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jamaophthalmol.2013.5692","article-title":"Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%","volume":"132","author":"Schoenberger","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0115","first-page":"47","article-title":"MnTBAP or catalase is more protective against oxidative stress in human retinal endothelial cells exposed to intermittent hypoxia than their co-administration (EUK-134)","volume":"3","author":"Quan","year":"2017","journal-title":"ROS J."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0120","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1021\/pr501238m","article-title":"Proteomic profiling of the retinas in a neonatal rat model of oxygen-induced retinopathy with a reproducible ion-current-based MS1 approach","volume":"14","author":"Tu","year":"2015","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0125","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1167\/iovs.13-13040","article-title":"Hydrogen peroxide accumulation in the choroid during intermittent hypoxia increases risk of severe oxygen-induced retinopathy in neonatal rats","volume":"54","author":"Beharry","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0130","first-page":"4353129","article-title":"Ocular adverse effects of intravitreal bevacizumab are potentiated by intermittent hypoxia in a rat model of oxygen-induced retinopathy","author":"Tan","year":"2017","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0135","first-page":"3015","article-title":"Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues","volume":"125","author":"Baker","year":"2013","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0140","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.semcancer.2005.06.009","article-title":"Gene expression perturbation in vitro\u2013a growing case for three-dimensional (3D) culture systems","volume":"15","author":"Birgersdotter","year":"2005","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0150","doi-asserted-by":"crossref","first-page":"81s","DOI":"10.18433\/J3T886","article-title":"Evolution of nonsteroidal anti-Inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond","volume":"11","author":"Rao","year":"2008","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000268030","article-title":"Blood supply of the retina","volume":"29","author":"Funk","year":"1997","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0160","first-page":"125","article-title":"Formation of unique biologically active prostaglandins in vivo by a non-cyclooxygenase free radical catalyzed mechanism","volume":"21A","author":"Morrow","year":"1991","journal-title":"Adv. Prostaglandin Thromboxane Leukot. Res."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0165","doi-asserted-by":"crossref","first-page":"9383","DOI":"10.1073\/pnas.87.23.9383","article-title":"A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism","volume":"87","author":"Morrow","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0170","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2174\/138161206776055985","article-title":"The isoprostanes\u2014unique products of arachidonate peroxidation: their role as mediators of oxidant stress","volume":"12","author":"Morrow","year":"2006","journal-title":"Curr. Pharm. Res."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0175","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1089\/ars.2006.8.1379","article-title":"Isoprostanes and related compounds: update 2006","volume":"8","author":"Milne","year":"2006","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0022-3476(05)81247-8","article-title":"Tissue levels of polyunsaturated fatty acids during early human development","volume":"120","author":"Martinez","year":"1992","journal-title":"J. Pediatr."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0185","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1007\/s11064-013-1123-z","article-title":"Reactive oxygen species from human astrocytes induced functional impairment and oxidative damage","volume":"38","author":"Sheng","year":"2013","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.biochem.69.1.145","article-title":"Cyclooxygenases: structural, cellular, and molecular biology","volume":"69","author":"Smith","year":"2000","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0195","first-page":"4574","article-title":"Thromboxane A2 is a mediator of cyclooxygenase-2 dependent endothelial migration and angiogenesis","volume":"59","author":"Daniel","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0200","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjp.0704705","article-title":"Regulation by PGE2 of the production of interleukin-6 macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts","volume":"136","author":"Inoue","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0205","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/01.CIR.97.1.99","article-title":"Vascular endothelial growth factor\/vascular permeability factor enhances vascular permeability via nitric oxide and prostacycline","volume":"97","author":"Murohara","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1026575610124","article-title":"The contributions of cyclooxygenase-2 to tumor angiogenesis","volume":"19","author":"Gately","year":"2000","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0215","first-page":"625","article-title":"Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo","volume":"62","author":"Leahy","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0220","first-page":"1546","article-title":"Regulation of retinal vascular endothelial growth factor and receptors in rabbits exposed to hyperoxia","volume":"43","author":"Ozaki","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0225","first-page":"1799","article-title":"Ibuprofen enhances retinal and choroidal blood flow autoregulation in newborn piglets","volume":"32","author":"Chemtob","year":"1991","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0230","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jpeds.2008.05.009","article-title":"Indomethacin and retinopathy of prematurity: the hidden paradox","volume":"153","author":"Hammerman","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0235","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1076\/ceyr.27.5.309.17222","article-title":"Ibuprofen improves oxygen-induced retinopathy in a mouse model","volume":"27","author":"Sharma","year":"2003","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0240","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1167\/iovs.02-0346","article-title":"Topical nepafenac inhibits ocular neovascularization","volume":"44","author":"Takahashi","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0245","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.exer.2006.07.011","article-title":"PGI2 opens potassium channels in retinal pericytes by cyclic AMP-stimulated, cross-activation of PKG","volume":"83","author":"Burnette","year":"2006","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0250","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1253\/circj.CJ-10-0195","article-title":"Prostacyclin in vascular diseases","volume":"74","author":"Kawabe","year":"2010","journal-title":"Circ. J."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0255","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","article-title":"Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2","volume":"96","author":"McAdam","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0260","doi-asserted-by":"crossref","first-page":"36772","DOI":"10.1542\/peds.82.3.367","article-title":"Changes in oxygen tension and effects on cyclooxygenase metabolites: II. Decrease of retinal prostacyclin in kittens exposed to hyperoxia","volume":"82","author":"Stuart","year":"1988","journal-title":"Pediatric"},{"key":"10.1016\/j.prostaglandins.2017.09.005_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v29.i1.10","article-title":"Scaffold: a novel carrier for cell and drug delivery","volume":"29","author":"Garg","year":"2012","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."}],"container-title":["Prostaglandins & Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882317300679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882317300679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:01:09Z","timestamp":1761098469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882317300679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":53,"alternative-id":["S1098882317300679"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2017.09.005","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human retinal endothelial cells and astrocytes cultured on 3-D scaffolds for ocular drug discovery and development","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2017.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}